LOGIN TO OUR AMALGEROL TRIAL DATABASE
Incorrect access data.
Register
FORGOT YOUR PASSWORD?

Enter your username or email address and we will send you a link to reset your password.

website.reset-password.success
website.reset-password.error
User Read Only User Full Access
Create new trial
de
AMALGEROL acts fungi-inhibiting in sunflowers and increases height, yield and oil content
AMALGEROL acts fungi-inhibiting in sunflowers and increases height, yield and oil content

# drought stress, Fungicide stress, Oil content, Shoot Development, yield

Sunflower

Hungary

AMALGEROL®

AMALGEROL acts fungi-inhibiting in sunflowers and increases height, yield and oil content

Sunflowers are an important field crop, particularly in the South-East of Europe. Sunflower oil is widely used and excellent for human health.

 

Sunflowers, however, get sometimes infected by fungi, e.g. Phoma Black Stem disease or Sclerotinia (white stems). In this standardised trial at the Robert Fleischmann Research Institute, we compared the effect of AMALGEROL on sunflowers, the effect of an AMALGEROL+ Contans combination and the classical fungicide Iprodion (permission ended 2018) to an untreated control. Contans is a biological fungicide with a strain of Coniothyrium minitans.

 

The summer of 2013 was very dry with several weeks without precipitation. Under these circumstances, the "AMALGEROL effect" is even more pronounced (in terms of yield increase to the untreated control).

 

AMALGEROL as well as the AMALGEROL + Contans combination had both very positive effects on the sunflowers in terms of plant height (Fig. 1), yield increase (Fig. 2) and fungi reduction (Table 1).

 

In addition, AMALGEROL increased the oil content from 40,2 % in the untreated control to 42,2 % (equal for AMALGEROL and AMALGEROL+Contans). In the Iprodion variant the oil content was on a similar level (42,1 %). 

 

+ 20-27 % more yield

+ plants 20 cm higher after 8 weeks

+ fungi-inhibiting effect

+ 2 % higher oil content  

NEWSLETTER

Stay updated with the latest trials and news from AMALGEROL.

Successfully registered for newsletter
Unfortunately something didn't work.

To read the entire article, please log in.